Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

GSK Awarded Up to $200 Million by U.S. Government to Develop New Antibiotics

Published: Friday, May 24, 2013
Last Updated: Friday, May 24, 2013
Bookmark and Share
Funding will support development of drugs to fight antibiotic resistance and bioterrorism.

GlaxoSmithKline (GSK) plc and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), have agreed to a first of its kind collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism.

This public-private agreement marks the first time that HHS has taken a “portfolio approach” to funding drug development with a private sector company.

This unique collaboration provides flexibility to move funding around GSK’s antibacterial portfolio, rather than focusing on just one drug candidate and allow medicines to be studied for the potential treatment of both conventional and biothreat pathogens.

Under the terms of the agreement, HHS will provide $40 million for the initial 18-month agreement and up to a total of $200 million if the agreement is renewed over five years.

The treatment of drug resistant bacterial infections is predicted to become a global crisis due to the scarcity of new antibiotics in the pharmaceutical industry’s pipeline and a decrease in investment in research and development.

Many companies have in recent years withdrawn from antibacterial R&D due to the scientific challenges and a lower return on investment, affecting the ability to treat bacterial infections and compromising our preparedness to tackle biothreat pathogens.

Consequently, public-private partnership is important to help sustain effort in this area of science.

“There is an urgent need to address antibiotic resistance and new models are needed to deal with this challenging area of drug development,” said David Payne, head of GSK’s Antibacterial Discovery Performance Unit.

Payne continued, “We strongly believe that innovative public-private partnerships such as this are integral to solving this critical healthcare issue and we are delighted to work with BARDA in a more strategic way.”

The work under this agreement will be governed by a BARDA-GSK joint oversight committee that will monitor progress, make decisions on the allocation of funds and decide on the addition or removal of drug candidates from the portfolio.

GSK is an industry leader in government research collaborations and has had contracts with BARDA and other agencies for vaccines and antibiotics development.

In March, GSK and the Texas A&M System and GlaxoSmithKline received U.S. government approval to establish an influenza vaccine facility in Texas.

As one of the few large pharmaceutical companies still pursuing antibacterial research, GSK also has creative collaborations and funding partnerships with other companies, academia, and funding bodies such as the Innovative Medicines Initiative, Europe’s largest public-private initiative and the Defense Threat Reduction Agency, which is part of the U.S. Department of Defense.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GSK and Impax Pharmaceuticals Terminate Their Collaboration on IPX066
Both Companies end collaboration for the development and commercialization of IPX066 outside the United States and Taiwan.
Tuesday, May 07, 2013
GSK and Impax Terminate Their Collaboration
The companies are terminating their collaboration for the development and commercialisation of IPX066 outside the United States and Taiwan.
Tuesday, April 30, 2013
GSK and GlaxoSmithKline Consumer Nigeria PLC Announces Agreement
GSK to increase its stake in GlaxoSmithKline Consumer Nigeria PLC.
Friday, November 30, 2012
GSK to Fully Acquire Cellzome for £61 Million
GSK to further expand its platform technology expertise with acquisition of chemical proteomics company.
Wednesday, May 16, 2012
GSK and University of Nottingham Collaborate to Create Centre of Excellence for Sustainable Chemistry
Innovative carbon neutral laboratory to be established on University Campus.
Friday, April 27, 2012
GlaxoSmithKline in Pioneering Collaboration with The University of Nottingham
A new facility focused on the development of ‘green chemistry’ technology is part of a pioneering new partnership.
Wednesday, December 01, 2010
APPLES Consortium to Develop Improved In-Line Liquid Monitoring Technologies to Manufacture High-Value Products
New sensor system to be based on Stratophase’s SpectroSens optical microchip technology.
Wednesday, March 31, 2010
GlaxoSmithKline Update: Government Orders for Pandemic (H1N1) 2009 Vaccine
GSK is supporting governments and health authorities around the world respond to the pandemic (H1N1) 2009 influenza strain.
Monday, August 10, 2009
GSK Extends Strategic Collaboration with Aspen
GSK to acquire 16% shareholding in Aspen in exchange for transfer of specialist products and manufacturing facility in Bad Oldesloe, Germany.
Thursday, May 14, 2009
GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company
Creates a new focused HIV business with the independence and sustainability to deliver improvements in treatment, access and shareholder value.
Friday, April 17, 2009
GlaxoSmithKline to Acquire Genelabs to Increase Focus on Small Molecule Therapies for Hepatitis C
Under the terms of the agreement, a subsidiary of GSK will commence a tender offer to acquire all of the outstanding shares of Genelabs common stock.
Thursday, October 30, 2008
GlaxoSmithKline and Tolerx Form Worldwide Collaboration for Development and Commercialization of Novel Medication
Collaboration aims to develop and commercialize a humanized anti-CD3 monoclonal antibody against type 1 diabetes and other autoimmune indications.
Wednesday, October 24, 2007
GlaxoSmithKline and Synta Announce Development and Commercialization Collaboration
The global collaboration agreement aim to develop and commercialize STA-4783 for the treatment of metastatic melanoma.
Thursday, October 11, 2007
GlaxoSmithKline Research Chooses Spotfire
Spotfire DecisionSite has been chosen by the IT team within GSK's Chemistry Domain.
Monday, October 02, 2006
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos